---
title: Antiparkinsonian Drugs
type: content
phase: 1
status: complete
priority: high
tags: [parkinson, levodopa, dopamine-agonists, MAO-B-inhibitors, COMT-inhibitors, anticholinergics, motor-symptoms]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antiparkinsonian Drugs

## Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. Understanding the pharmacologic approaches to restore dopamine function and manage motor and non-motor symptoms is essential for optimal patient care.

## Pathophysiology of Parkinson's Disease

### Basal Ganglia Circuitry

**Normal Function**:
- **Substantia nigra** (pars compacta) → dopamine → **striatum** (caudate, putamen)
- Dopamine modulates balance between:
  - **Direct pathway**: Facilitates movement (D1 receptors)
  - **Indirect pathway**: Inhibits movement (D2 receptors)

**In Parkinson's Disease**:
- ↓Dopamine in striatum (>80% loss when symptoms appear)
- ↑Indirect pathway activity → ↑inhibition of thalamus
- Result: **Bradykinesia, rigidity, tremor**

### Motor Symptoms (Cardinal Features)

**TRAP Mnemonic**:
1. **Tremor**: Resting tremor (4-6 Hz, "pill-rolling")
2. **Rigidity**: "Cogwheel" or "lead-pipe"
3. **Akinesia/Bradykinesia**: Slowness of movement, decreased amplitude
4. **Postural instability**: Balance problems, falls (late)

**Other Motor**:
- Micrographia (small handwriting)
- Hypomimia (masked face)
- Shuffling gait, festination
- Freezing of gait
- Hypophonia (soft speech)

### Non-Motor Symptoms

- Autonomic: Orthostatic hypotension, constipation, urinary dysfunction
- Neuropsychiatric: Depression, anxiety, psychosis, dementia
- Sleep: REM sleep behavior disorder, insomnia
- Sensory: Anosmia (early), pain
- Cognitive impairment

---

## Classification of Antiparkinsonian Drugs

### Dopamine Replacement/Enhancement

1. **Levodopa** (with carbidopa or benserazide)
   - Dopamine precursor

2. **Dopamine Agonists**:
   - Ergot: Bromocriptine, cabergoline (rarely used)
   - Non-ergot: Pramipexole, ropinirole, rotigotine, apomorphine

3. **MAO-B Inhibitors**:
   - Selegiline, rasagiline, safinamide

4. **COMT Inhibitors**:
   - Entacapone, tolcapone, opicapone

### Other Mechanisms

5. **Anticholinergics**:
   - Benztropine, trihexyphenidyl

6. **Amantadine**:
   - NMDA antagonist, dopamine release

7. **Adenosine A2A Antagonist**:
   - Istradefylline

---

## Levodopa (L-DOPA)

### Mechanism of Action

**Rationale**: Replace deficient dopamine

**Why Levodopa, Not Dopamine?**:
- **Dopamine cannot cross BBB** (polar molecule)
- **Levodopa crosses BBB** via large neutral amino acid transporter (LAT)
- Converted to dopamine in brain by **aromatic amino acid decarboxylase (AADC)**

**Pathway**:
1. Levodopa → crosses BBB
2. AADC in striatum → dopamine
3. Dopamine activates D1, D2 receptors

**Problem**: Peripheral conversion
- **95% of levodopa converted to dopamine peripherally** (before BBB)
- Peripheral dopamine → nausea, vomiting, hypotension
- **Solution**: Combine with peripheral AADC inhibitor

### Formulations

**Levodopa/Carbidopa (Sinemet)**:
- **Carbidopa**: Peripheral AADC inhibitor (does NOT cross BBB)
- Blocks peripheral conversion → ↑levodopa reaching brain, ↓side effects
- Ratio: 10:1 or 4:1 (carbidopa:levodopa)
- Formulations: IR, CR (controlled-release), ODT

**Levodopa/Benserazide** (Madopar):
- Used in Europe
- Similar mechanism

**Levodopa/Carbidopa/Entacapone** (Stalevo):
- Triple combination (adds COMT inhibitor)
- See COMT inhibitors below

**Inhaled Levodopa** (Inbrija):
- For "OFF" episodes
- Rapid onset

**Levodopa/Carbidopa Intestinal Gel** (Duopa):
- Continuous infusion via PEG-J tube
- For advanced PD with motor fluctuations

### Pharmacokinetics

**Absorption**:
- Rapid absorption in small intestine (LAT transporter)
- **Competition with dietary amino acids** → take on empty stomach
- Erratic absorption in advanced disease (gastroparesis)

**Distribution**:
- Crosses BBB via LAT (competes with dietary proteins)

**Metabolism**:
- **Peripheral**: AADC → dopamine, COMT → 3-O-methyldopa
- **Central**: AADC → dopamine (therapeutic)

**Half-life**: 1-2 hours (short → requires frequent dosing)

### Clinical Uses

1. **Parkinson's disease** - **most effective drug**
   - Gold standard for motor symptoms
   - All stages (early and advanced)

**Efficacy**:
- **Most effective** for bradykinesia, rigidity
- Less effective for tremor (dopamine agonists may be better)
- Ineffective for postural instability (late feature)

### Adverse Effects

**Early/Peripheral** (reduced by carbidopa):

1. **GI Effects**:
   - Nausea, vomiting (peripheral dopamine → CTZ)
   - Anorexia

2. **Cardiovascular**:
   - **Orthostatic hypotension** (peripheral dopamine → vasodilation)
   - Arrhythmias (rarely)

**Long-Term/Central**:

3. **Motor Complications** (develop over years):

   a. **Motor Fluctuations**:
   - **"Wearing OFF"**: Return of symptoms before next dose (↓duration of benefit)
     - Initially 4-6 hours → 2-3 hours → <1 hour
   - **"ON-OFF" phenomenon**: Sudden, unpredictable fluctuations
   - **Delayed ON** or **dose failures**

   b. **Dyskinesias** (involuntary movements):
   - **Peak-dose dyskinesia** (most common):
     - Choreiform movements at peak levodopa level
     - Affects face, trunk, limbs
   - **Biphasic dyskinesia**: At rising and falling levels
   - **"OFF" dystonia**: Painful dystonia when levodopa low (e.g., early morning)

   **Risk Factors for Motor Complications**:
   - Duration of levodopa therapy
   - Younger age at onset (<60 years)
   - Higher doses

4. **Psychiatric/Cognitive**:
   - **Hallucinations, psychosis** (dopamine excess in mesolimbic pathway)
     - Visual hallucinations most common
     - Insight usually preserved initially
   - **Impulse control disorders** (less than dopamine agonists)
   - Confusion, agitation
   - Sleep disturbances

5. **Other**:
   - Darkening of urine, sweat, saliva (dopamine metabolites - benign)
   - Neuropathy (rare, with high doses)

**Contraindications**:
- **Non-selective MAOIs** (phenelzine, tranylcypromine) → hypertensive crisis
  - MAO-B selective (selegiline, rasagiline) safe with levodopa
- Narrow-angle glaucoma (controversial)
- Melanoma (dopamine may promote - controversial)

### Drug Interactions

**Problematic**:
- **Non-selective MAOIs**: Hypertensive crisis (contraindicated)
- **Antipsychotics** (D2 antagonists): Block therapeutic effect, worsen parkinsonism
- **Metoclopramide**: D2 antagonist, worsens parkinsonism
- **Dietary proteins**: Compete for absorption and BBB transport

**Helpful**:
- **MAO-B inhibitors** (selegiline, rasagiline): ↓dopamine breakdown
- **COMT inhibitors** (entacapone, tolcapone): ↓levodopa breakdown

### Dosing Strategies

**Initial**:
- Start low: Carbidopa/levodopa 25/100 mg TID
- Titrate slowly
- Take 30-60 minutes before meals (avoid protein competition)

**Maintenance**:
- Typical: 300-1200 mg/day levodopa (divided doses)
- **Need ≥75 mg/day carbidopa** to block peripheral conversion

**Advanced Disease** (motor fluctuations):
- ↑Frequency (q3h instead of q4-6h)
- Use CR formulation (smoother levels)
- Add COMT inhibitor (extend duration)
- Add MAO-B inhibitor
- Adjust timing relative to meals
- Consider continuous infusion (Duopa)

### Management of Motor Complications

**"Wearing OFF"**:
- ↑Dose frequency (shorter intervals)
- Add COMT inhibitor (entacapone)
- Add MAO-B inhibitor
- Use CR formulation
- Take on empty stomach

**Peak-Dose Dyskinesias**:
- ↓Individual dose, ↑frequency
- Add amantadine (anti-dyskinetic effect)
- Use dopamine agonist (smoother effect)

**OFF Dystonia**:
- Bedtime dose of CR levodopa
- Dopamine agonist at bedtime

**Clinical Pearls**:
- **"Start low, go slow" not always best** - adequate dosing important for symptom control
- **Don't delay levodopa in young patients** for fear of dyskinesias (motor complications inevitable)
- **Protein spacing**: Take levodopa 30-60 min before meals or 1-2 hours after
- **"Levodopa honeymoon"**: First few years with excellent response, no complications

---

## Dopamine Agonists

### Mechanism of Action

**Direct D2 (and D1) receptor agonists** in striatum
- Bypass need for dopamine synthesis
- **Longer half-life** than levodopa → smoother dopaminergic stimulation
- Less motor complications (dyskinesias) early on

### Classification

**Ergot-Derived** (rarely used now):
- Bromocriptine, cabergoline, pergolide
- **Risk**: Cardiac valvular fibrosis, retroperitoneal fibrosis

**Non-Ergot** (preferred):
- **Pramipexole** (Mirapex)
- **Ropinirole** (Requip)
- **Rotigotine** (Neupro - transdermal patch)
- **Apomorphine** (Apokyn - SC injection)

### Individual Agents

#### Pramipexole (Mirapex)

**Receptor**: D2 > D3 >> D1 agonist

**Pharmacokinetics**:
- Oral (IR, ER)
- **Renal excretion** (90% unchanged) - adjust in renal impairment
- Half-life: 8-12 hours

**Clinical Uses**:
1. **Parkinson's disease**:
   - Monotherapy (early disease - delay levodopa)
   - Adjunct to levodopa (reduce motor fluctuations)
2. **Restless legs syndrome** (FDA-approved)

**Advantages**:
- **May delay need for levodopa** (early PD)
- ↓Motor fluctuations, dyskinesias vs. levodopa alone
- **Good for tremor** (may be better than levodopa)
- Longer half-life → smoother effect

**Adverse Effects**:

**Common**:
- Nausea, vomiting (dopamine in CTZ)
- Somnolence, fatigue
- Dizziness, orthostatic hypotension (worse than levodopa)
- Hallucinations, psychosis (more than levodopa)
- Peripheral edema

**Serious**:
- **Sudden sleep attacks** ("sleep attacks"):
  - **Falling asleep without warning** (even while driving)
  - **Warn patients** - caution with driving, operating machinery
- **Impulse control disorders** (10-20%):
  - Pathological gambling
  - Compulsive shopping, eating, sexual behavior
  - **Dose-related**, reversible with discontinuation
  - **Screen regularly**
- **Dopamine dysregulation syndrome** (addiction-like behavior to medication)

**Dosing**:
- Start: 0.125 mg TID
- Titrate slowly over weeks
- Usual: 0.5-1.5 mg TID (max 4.5 mg/day)
- ER: Once daily

#### Ropinirole (Requip)

**Receptor**: D2, D3 agonist

**Pharmacokinetics**:
- Oral (IR, ER)
- Hepatic metabolism (CYP1A2)
- Half-life: 6 hours

**Clinical Uses**: Similar to pramipexole
1. Parkinson's disease
2. Restless legs syndrome

**Adverse Effects**: Similar to pramipexole

**Dosing**:
- Start: 0.25 mg TID
- Titrate slowly
- Usual: 3-9 mg TID (max 24 mg/day)

#### Rotigotine (Neupro)

**Formulation**: **Transdermal patch** (24-hour)

**Receptor**: D1, D2, D3 agonist

**Pharmacokinetics**:
- Continuous delivery (steady state)
- Half-life: 5-7 hours

**Advantages**:
- **Once-daily application** (compliance)
- **Steady levels** (no peaks/troughs)
- **Useful in gastroparesis** (bypasses GI)
- Good for early morning "OFF" symptoms

**Adverse Effects**:
- **Application site reactions** (50%) - rotate sites
- Similar to oral dopamine agonists (nausea, somnolence, impulse control)

**Dosing**:
- Start: 2 mg/24h patch
- Titrate weekly
- Usual: 4-8 mg/24h (max 16 mg/24h)

#### Apomorphine (Apokyn)

**Formulation**: **Subcutaneous injection** (pen injector)

**Receptor**: D1, D2 agonist

**Clinical Uses**:
- **Acute "OFF" episodes** (rescue therapy)
- Advanced Parkinson's with motor fluctuations

**Pharmacokinetics**:
- **Rapid onset**: 10-20 minutes
- Short duration: 60-90 minutes

**Advantages**:
- **Fastest-acting dopamine agonist**
- Good for unpredictable "OFF" episodes

**Adverse Effects**:
- Severe nausea, vomiting (requires antiemetic prophylaxis)
- Orthostatic hypotension (severe)
- **QTc prolongation**
- Injection site nodules

**Pretreatment**:
- **Trimethobenzamide** (antiemetic) required 3 days before starting
- Start antiemetic 3 days prior, continue indefinitely

**Contraindications**:
- **5-HT3 antagonists** (ondansetron, granisetron) → severe hypotension (contraindicated)

**Dosing**:
- Test dose: 0.2 mL (2 mg) SC
- Titrate based on response
- PRN for "OFF" episodes (max 5 doses/day)

#### Bromocriptine (Parlodel)

**Class**: **Ergot derivative**

**Receptor**: D2 agonist

**Clinical Uses**:
1. Parkinson's disease (less commonly used now)
2. **Hyperprolactinemia** (primary use)
3. Acromegaly

**Adverse Effects**:
- **Cardiac valvular fibrosis** (fibrosis of heart valves):
  - **Major concern** with ergot derivatives
  - Requires echocardiographic monitoring
- **Retroperitoneal fibrosis**, **pleuropulmonary fibrosis**
- Other dopamine agonist effects

**Note**: **Largely replaced by non-ergot agents** due to fibrosis risk

### General Considerations for Dopamine Agonists

**Advantages**:
- **Delay motor complications** (dyskinesias) vs. levodopa monotherapy
- **Longer half-life** → smoother effect
- **May delay need for levodopa** (early disease)
- Good for tremor, RLS

**Disadvantages**:
- **Less effective than levodopa** for motor symptoms
- **More hallucinations, psychosis** than levodopa
- **Impulse control disorders** (screen regularly)
- **Sudden sleep attacks** (caution driving)
- **Peripheral edema**

**Strategy**:
- **Early PD** (<65 years): Consider starting with dopamine agonist (delay levodopa, reduce dyskinesias)
- **Older patients** (>70 years): Start with levodopa (cognitive side effects from agonists)
- **Advanced PD**: Add to levodopa (reduce fluctuations, lower levodopa dose)

**Discontinuation**:
- **Taper slowly** (over weeks) to prevent withdrawal syndrome (anxiety, depression, pain, drug craving)

---

## MAO-B Inhibitors

### Mechanism of Action

**Monoamine oxidase B (MAO-B)**:
- Enzyme that metabolizes dopamine
- Predominant form in striatum

**MAO-B Inhibitors**:
- Block dopamine breakdown in striatum
- ↑Dopamine availability
- **Selective for MAO-B** (not MAO-A) → no tyramine reaction

### Individual Agents

#### Selegiline (Eldepryl, Zelapar)

**Mechanism**: **Irreversible MAO-B inhibitor**

**Pharmacokinetics**:
- Oral (tablet, ODT)
- Metabolized to amphetamine metabolites (methamphetamine, amphetamine)

**Clinical Uses**:
1. Parkinson's disease (adjunct to levodopa or monotherapy)

**Neuroprotection**:
- Theoretical neuroprotective effect (controversial)
- May slow disease progression (unclear)

**Advantages**:
- May allow ↓levodopa dose
- Extend levodopa duration ("wearing OFF")
- Once or twice daily dosing

**Adverse Effects**:
- **Insomnia** (amphetamine metabolites - dose in morning)
- Nausea, dizziness
- Orthostatic hypotension (when combined with levodopa)
- Hallucinations (↑dopamine)
- **At high doses** (>10 mg/day): Loses MAO-B selectivity → tyramine reaction possible

**Drug Interactions**:
- **Safe with levodopa** (designed for this combination)
- **Avoid with meperidine** (serotonin syndrome risk)
- **Avoid with SSRIs/SNRIs** (theoretical serotonin syndrome - use with caution)

**Dosing**:
- 5 mg PO daily or BID (morning, noon)
- Max: 10 mg/day (maintain selectivity)

**Note**: Also used for depression (transdermal patch - Emsam, higher doses)

#### Rasagiline (Azilect)

**Mechanism**: **Irreversible MAO-B inhibitor**

**Advantages over Selegiline**:
- **No amphetamine metabolites** → less insomnia
- Once-daily dosing
- May have neuroprotective effects (preclinical)

**Pharmacokinetics**:
- Oral
- Hepatic metabolism

**Clinical Uses**: Parkinson's disease (monotherapy or adjunct)

**Adverse Effects**:
- Similar to selegiline but **less insomnia**
- Nausea, dizziness, orthostatic hypotension
- Hallucinations
- Dyskinesias (when combined with levodopa)

**Dosing**:
- Monotherapy: 1 mg daily
- Adjunct to levodopa: 0.5-1 mg daily

#### Safinamide (Xadago)

**Mechanism**:
- **Reversible MAO-B inhibitor** (unlike selegiline, rasagiline)
- Also blocks sodium channels, modulates glutamate

**Clinical Uses**: Parkinson's disease (adjunct to levodopa)

**Advantages**:
- Reversible (shorter washout)
- Additional non-dopaminergic mechanisms

**Adverse Effects**: Similar to other MAO-B inhibitors

**Dosing**: 50-100 mg daily

### General Considerations

**Advantages**:
- Well-tolerated
- Once-daily dosing
- May have neuroprotective effects
- **Extend levodopa duration**

**Disadvantages**:
- Modest efficacy (less than levodopa or dopamine agonists)
- May exacerbate levodopa side effects (hallucinations, dyskinesias)

**Dietary Restrictions**:
- **None required** (MAO-B selective - does not inhibit MAO-A in gut)
- Tyramine reaction not a concern at therapeutic doses

---

## COMT Inhibitors

### Mechanism of Action

**Catechol-O-Methyltransferase (COMT)**:
- Enzyme that metabolizes levodopa and dopamine
- Peripheral and central

**COMT Inhibitors**:
- Block COMT → ↓levodopa metabolism
- **↑Levodopa half-life**, ↑area under curve
- **More levodopa reaches brain**
- **Must be given with levodopa** (no effect alone)

### Individual Agents

#### Entacapone (Comtan)

**Mechanism**: **Peripheral COMT inhibitor** (does not cross BBB well)

**Pharmacokinetics**:
- Oral
- Short half-life (0.5 hours)
- Given with each levodopa dose

**Clinical Uses**:
- **Adjunct to levodopa/carbidopa** for motor fluctuations ("wearing OFF")

**Efficacy**:
- ↑Levodopa half-life by 50%
- ↑"ON" time by 1-2 hours/day
- Allows ↓levodopa dose (or extend interval)

**Adverse Effects**:
- **Diarrhea** (10%, can be severe):
  - Dose-related
  - May require discontinuation
- **Urine discoloration** (brownish-orange - benign, due to metabolites)
- **Enhanced levodopa side effects**: Dyskinesias, hallucinations, nausea
  - May require ↓levodopa dose by 10-30%

**Dosing**:
- 200 mg with each levodopa dose (max 8 doses/day = 1600 mg)

**Formulation**:
- **Stalevo**: Triple combination (levodopa/carbidopa/entacapone)
  - Convenient single pill

#### Tolcapone (Tasmar)

**Mechanism**: **Peripheral and central COMT inhibitor** (crosses BBB)

**Advantages over Entacapone**:
- More potent (central + peripheral inhibition)
- TID dosing (vs. with each levodopa dose)

**Disadvantages**:
- **Hepatotoxicity** (rare but fatal):
  - **3 deaths** in clinical trials
  - **Black Box Warning**
  - **Restricted use**: Requires informed consent, LFT monitoring
  - Reserve for patients who don't respond to entacapone

**Monitoring**:
- **LFTs every 2 weeks** for first year, then every 4 weeks
- Discontinue if ALT >2x ULN or symptoms of hepatitis

**Clinical Uses**: Advanced PD with motor fluctuations (second-line to entacapone)

**Dosing**: 100-200 mg TID

**Note**: **Rarely used** due to hepatotoxicity risk

#### Opicapone (Ongentys)

**Mechanism**: Peripheral COMT inhibitor (like entacapone)

**Advantages**:
- **Once-daily dosing** (long-acting)
- May be more potent than entacapone

**Dosing**: 50 mg daily at bedtime

**Status**: Newer agent, available in Europe, FDA-approved in US (2020)

---

## Anticholinergics

### Mechanism of Action

**Rationale**:
- Parkinson's: ↓Dopamine, ↑relative cholinergic activity in striatum
- Block muscarinic receptors → restore balance

**Effect**: Primarily **tremor** reduction

### Individual Agents

**Benztropine** (Cogentin):
- 1-2 mg BID

**Trihexyphenidyl** (Artane):
- 1-2 mg TID

### Clinical Uses

1. **Tremor-predominant Parkinson's**:
   - Modest benefit for tremor (less effective for bradykinesia, rigidity)
2. **Drug-induced parkinsonism** (antipsychotics):
   - Effective for extrapyramidal symptoms (EPS)
3. **Young patients** with tremor-predominant disease

### Adverse Effects

**Peripheral Anticholinergic**:
- Dry mouth, blurred vision
- Constipation, urinary retention
- Mydriasis

**Central Anticholinergic**:
- **Cognitive impairment, confusion, memory problems**
- **Hallucinations**
- Delirium (especially elderly)

**Contraindications**:
- **Elderly** (cognitive side effects)
- Narrow-angle glaucoma
- BPH, urinary retention
- Dementia

### Clinical Pearls

- **Avoid in elderly** (>70 years) - cognitive side effects
- **Modest efficacy** - limited role
- **Better for tremor** than other motor symptoms
- **Largely replaced** by other agents

---

## Amantadine

### Mechanism of Action

**Multiple mechanisms**:
1. **NMDA receptor antagonist** (primary)
2. ↑Dopamine release
3. ↓Dopamine reuptake
4. Anticholinergic effects (weak)

### Clinical Uses

1. **Parkinson's disease** (adjunct):
   - **Dyskinesias**: **Best agent for levodopa-induced dyskinesias**
   - Motor symptoms (mild efficacy)
2. **Drug-induced parkinsonism** (antipsychotics)
3. **Influenza A prophylaxis/treatment** (historical - resistance now common)

**Unique Benefit**: **Anti-dyskinetic effect**
- Only medication that reduces levodopa-induced dyskinesias
- Mechanism unclear (NMDA antagonism?)

### Adverse Effects

**Common**:
- **Livedo reticularis** (mottled skin discoloration - legs):
  - Benign, reversible
  - Due to peripheral vasoconstriction
- Peripheral edema (ankle swelling)
- Dry mouth, constipation (anticholinergic)

**CNS**:
- Hallucinations, confusion (especially elderly)
- Insomnia, vivid dreams
- Dizziness

**Renal**:
- Renally excreted → **dose adjustment in renal impairment**

### Dosing

- Start: 100 mg daily
- Usual: 100 mg BID or TID
- Max: 400 mg/day
- **Adjust for renal function**

### Clinical Pearls

- **First-line for dyskinesias** (levodopa-induced)
- **Must adjust dose in renal impairment** (accumulation → hallucinations)
- **Livedo reticularis benign** but noticeable

---

## Treatment Approach to Parkinson's Disease

### Early Parkinson's Disease

**Goals**: Symptom control, maintain quality of life, delay complications

**Initial Treatment Options**:

1. **Age <60-65 years**:
   - **Dopamine agonist** (pramipexole, ropinirole) OR **MAO-B inhibitor**:
     - Delay levodopa → delay motor complications
   - Add levodopa when symptoms require (inevitable)

2. **Age >70 years** OR **cognitive impairment**:
   - **Start with levodopa**:
     - Most effective
     - Better tolerated (less hallucinations, impulse control than agonists)

3. **Tremor-predominant, minimal disability**:
   - MAO-B inhibitor or anticholinergic (if young)

**Rationale for Delaying Levodopa** (controversial):
- Motor complications (dyskinesias, fluctuations) develop over time
- Dopamine agonists have fewer motor complications early
- **However**: Levodopa more effective, quality of life benefit
- **Modern view**: Don't withhold levodopa unnecessarily (complications may be inevitable)

### Moderate Parkinson's Disease

**Levodopa Initiation**:
- Start when symptoms interfere with function
- Combine with carbidopa
- Titrate to lowest effective dose

**Monotherapy vs. Combination**:
- Start with levodopa monotherapy
- Add adjuncts as needed (dopamine agonist, MAO-B inhibitor, COMT inhibitor)

### Advanced Parkinson's Disease (Motor Fluctuations)

**"Wearing OFF"**:
- ↑Levodopa frequency (q3h instead of q4-6h)
- Add COMT inhibitor (entacapone) → extend duration
- Add MAO-B inhibitor
- Use CR formulation

**Dyskinesias**:
- ↓Individual levodopa dose, ↑frequency
- **Add amantadine** (anti-dyskinetic)
- Consider deep brain stimulation

**Refractory Symptoms**:
- Continuous levodopa infusion (Duopa - intestinal gel)
- Apomorphine (SC injection for "OFF" episodes)
- **Deep brain stimulation** (DBS):
  - Subthalamic nucleus or globus pallidus interna
  - Effective for motor fluctuations, dyskinesias
  - Does not slow disease progression

### Non-Motor Symptoms

**Depression**:
- SSRIs (sertraline, citalopram)
- Pramipexole (dopamine agonist - may help)

**Psychosis/Hallucinations**:
- ↓Antiparkinsonian medications (taper anticholinergics, amantadine, agonists first)
- If needed, add:
  - **Pimavanserin** (FDA-approved for Parkinson's psychosis):
    - 5-HT2A inverse agonist (no D2 blockade)
    - Does not worsen motor symptoms
  - **Quetiapine** (off-label):
    - Low D2 affinity
    - Less motor worsening
  - **Clozapine** (effective but requires monitoring)
- **Avoid typical antipsychotics** (worsen parkinsonism)

**Dementia**:
- **Rivastigmine** (FDA-approved for Parkinson's dementia):
  - Cholinesterase inhibitor
- Donepezil, memantine (off-label)

**Orthostatic Hypotension**:
- Non-pharmacologic (compression stockings, salt, fluids)
- Midodrine, fludrocortisone
- Droxidopa (FDA-approved for neurogenic orthostatic hypotension)

**Constipation**:
- Stool softeners, laxatives
- Polyethylene glycol

---

## Special Considerations

### Drug-Induced Parkinsonism

**Causes**:
- **Antipsychotics** (D2 antagonists):
  - Typical > atypical
  - Risperidone, paliperidone (high D2 affinity)
- **Antiemetics**: Metoclopramide, prochlorperazine (D2 antagonists)
- Valproate, lithium
- Calcium channel blockers (rare): Flunarizine, cinnarizine

**Management**:
1. **Stop offending agent** (if possible)
2. **Switch antipsychotic** to low D2 affinity (quetiapine, clozapine, pimavanserin)
3. **Add anticholinergic** (benztropine) or amantadine
4. **Avoid levodopa** (ineffective for drug-induced parkinsonism)

### Parkinson's vs. Parkinson-Plus Syndromes

**Parkinson-Plus Syndromes**:
- Multiple system atrophy (MSA)
- Progressive supranuclear palsy (PSP)
- Corticobasal degeneration
- Dementia with Lewy bodies

**Key Difference**:
- **Poor response to levodopa** (helps distinguish from idiopathic PD)
- Additional features (autonomic failure, vertical gaze palsy, etc.)

**Treatment**: Supportive (levodopa trial reasonable but often ineffective)

---

## Clinical Pearls

1. **Levodopa most effective drug** for Parkinson's motor symptoms
2. **Combine levodopa with carbidopa** (blocks peripheral conversion)
3. **Motor complications inevitable** with long-term levodopa (dyskinesias, fluctuations)
4. **Dopamine agonists** delay motor complications but less effective than levodopa
5. **Start dopamine agonists in young patients** (<60 years) to delay levodopa
6. **Start levodopa in elderly** (>70 years) - better tolerated, more effective
7. **MAO-B inhibitors extend levodopa duration** - no dietary restrictions (selective)
8. **Entacapone (COMT inhibitor)** extends levodopa duration - watch for diarrhea
9. **Amantadine best for dyskinesias** (levodopa-induced)
10. **Avoid anticholinergics in elderly** (cognitive side effects)
11. **Impulse control disorders with dopamine agonists** - screen regularly
12. **Pimavanserin for Parkinson's psychosis** (does not worsen motor symptoms)
13. **Avoid typical antipsychotics** in Parkinson's (worsen motor symptoms)
14. **Protein spacing important** - take levodopa on empty stomach

---

## Key Takeaways

1. **Levodopa**: Dopamine precursor, most effective, combine with carbidopa, motor complications develop
2. **Motor complications**: Wearing OFF (↑frequency, add COMT/MAO-B inhibitor), dyskinesias (↓dose, add amantadine)
3. **Dopamine agonists**: Pramipexole, ropinirole (D2 agonists), delay motor complications, impulse control disorders
4. **MAO-B inhibitors**: Selegiline, rasagiline (↓dopamine breakdown), extend levodopa, no dietary restrictions
5. **COMT inhibitors**: Entacapone (↓levodopa metabolism), extend duration, diarrhea
6. **Amantadine**: NMDA antagonist, best for dyskinesias
7. **Anticholinergics**: Tremor benefit, avoid in elderly (cognitive effects)
8. **Treatment approach**: Young patients (start agonist), elderly (start levodopa), add adjuncts as needed
9. **Non-motor**: Depression (SSRIs), psychosis (pimavanserin, quetiapine), dementia (rivastigmine)
10. **Drug-induced parkinsonism**: Stop offending agent, add anticholinergic, levodopa ineffective

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. American Academy of Neurology Practice Guidelines for Parkinson's Disease
4. Olanow CW, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004.
5. Fox SH, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Mov Disord. 2018.
6. FDA Drug Safety Communications - Parkinson's Disease Medications
